Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 24, No 10 (April 1), 2006: pp. 1535-1541
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.04.2978

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kager, L.
Right arrow Articles by Bielack, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kager, L.
Right arrow Articles by Bielack, S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Skip Metastases in Osteosarcoma: Experience of the Cooperative Osteosarcoma Study Group

Leo Kager, Andreas Zoubek, Ulrike Kastner, Beate Kempf-Bielack, Jenny Potratz, Rainer Kotz, G. Ulrich Exner, Christiane Franzius, Susanna Lang, Rainer Maas, Heribert Jürgens, Helmut Gadner, Stefan Bielack

From the St Anna Children's Hospital; Departments of Pathology and Orthopedics, University Hospital Vienna, Vienna, Austria; Department of Orthopedics, University Hospital Zürich, Zürich, Switzerland; Diagnostic Radiology, Hamburg; Department of Nuclear Medicine, University Hospital Muenster; Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster; and Olgahospital, Pediatrics 5–Oncology, Hematology, Immunology, Stuttgart, Germany

Address reprint requests to Stefan Bielack, MD, Olgahospital, Pediatrics 5, Bismarckstr 8, D-70176 Stuttgart, Germany; e-mail: coss{at}olgahospital-stuttgart.de

PURPOSE: The outlook for patients with osteosarcoma who present with synchronous regional bone metastases (skip metastases), either in the primary bone site or transarticular, is considered to be extremely poor. This study was conducted to further investigate the prognostic implication of skip metastases in osteosarcoma.

PATIENTS AND METHODS: The authors retrospectively analyzed the collected data of 1,765 consecutive patients with newly diagnosed high-grade osteosarcoma of bone who were registered in the neoadjuvant Cooperative Osteosarcoma Study Group studies and identified 24 patients (1.4%) with unequivocally proven skip metastases. All 24 patients were treated by an aggressive surgical approach coupled with polychemotherapy. Demographic, diagnostic, tumor, and treatment-related variables and response and survival data were analyzed.

RESULTS: Skip metastases were identified preoperatively in 11 of 24 patients by bone scan, eight of 22 patients by plain x-ray, 15 of 18 patients by magnetic resonance imaging, and five of 10 patients by computed tomography. A complete surgical remission (CSR) of all clinically detectable tumor sites was achieved in 22 of 24 patients during front-line therapy. With a median follow-up time of 4.4 years (8 years for survivors) from diagnosis, 12 patients were alive, all of whom were in continuous CSR. Survival did correlate with location of skip metastases and histologic response to neoadjuvant chemotherapy.

CONCLUSION: Synchronous regional bone metastases are rare in osteosarcoma, and preoperative detection relies on appropriate diagnostic imaging. Aggressive multimodal therapy holds the promise to achieve prolonged survival, especially in patients in whom these metastases occur within the same bone as the primary lesion and whose tumors respond well to chemotherapy.

Supported by Deutsche Krebshilfe and Forschungsinstitut fuer krebskranke Kinder, St Anna Kinderspital (Vienna, Austria).

Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003, and at the Sarcoma Meeting Stuttgart, Stuttgart, Germany, June 15-17, 2005.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J Am Acad Orthop SurgHome page
P. J. Messerschmitt, R. M. Garcia, F. W. Abdul-Karim, E. M. Greenfield, and P. J. Getty
Osteosarcoma
J. Am. Acad. Ortho. Surg., August 1, 2009; 17(8): 515 - 527.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. Akiyama, C. R. Dass, and P. F.M. Choong
Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway
Mol. Cancer Ther., November 1, 2008; 7(11): 3461 - 3469.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
T. Zwaga, J. V. M. G. Bovee, and H. M. Kroon
Best Cases from the AFIP: Osteosarcoma of the Femur with Skip, Lymph Node, and Lung Metastases
RadioGraphics, January 1, 2008; 28(1): 277 - 283.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online